NASDAQ:MBRX Moleculin Biotech (MBRX) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free MBRX Stock Alerts $5.91 +0.37 (+6.68%) (As of 05:21 PM ET) Add Compare Share Share Today's Range$5.18▼$6.2350-Day Range$4.68▼$10.3252-Week Range$4.34▼$24.75Volume77,685 shsAverage Volume31,254 shsMarket Capitalization$13.18 millionP/E RatioN/ADividend YieldN/APrice Target$101.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Moleculin Biotech alerts: Email Address Moleculin Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,555.8% Upside$101.67 Price TargetShort InterestHealthy0.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 25 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($10.27) to ($9.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.12 out of 5 starsMedical Sector363rd out of 938 stocksPharmaceutical Preparations Industry164th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingMoleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $101.67, Moleculin Biotech has a forecasted upside of 1,555.8% from its current price of $6.14.Amount of Analyst CoverageMoleculin Biotech has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.09% of the float of Moleculin Biotech has been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently decreased by 98.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MBRX. Previous Next 3.0 News and Social Media Coverage News SentimentMoleculin Biotech has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Moleculin Biotech this week, compared to 1 article on an average week.Search Interest4 people have searched for MBRX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows5 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Moleculin Biotech is held by insiders.Percentage Held by InstitutionsOnly 15.52% of the stock of Moleculin Biotech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Moleculin Biotech are expected to grow in the coming year, from ($10.27) to ($9.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moleculin Biotech is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moleculin Biotech is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Moleculin Biotech Stock (NASDAQ:MBRX)Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.Read More MBRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MBRX Stock News HeadlinesMarch 28, 2024 | finance.yahoo.comMoleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 28, 2024 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.comMarch 28, 2024 | DTI (Ad)How you can target big results without spending big money!While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades! March 28, 2024 | americanbankingnews.comEquities Analysts Set Expectations for Moleculin Biotech, Inc.'s FY2028 Earnings (NASDAQ:MBRX)March 27, 2024 | finance.yahoo.comMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLMarch 27, 2024 | prnewswire.comMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityMarch 27, 2024 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Price Target Lowered to $20.00 at Maxim GroupMarch 26, 2024 | finance.yahoo.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 25, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialMarch 25, 2024 | markets.businessinsider.comMoleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AMLMarch 25, 2024 | finance.yahoo.comMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialMarch 23, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports Full Year 2023 Financial ResultsMarch 22, 2024 | investorplace.comMBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023March 22, 2024 | finance.yahoo.comMoleculin Biotech Inc Reports Fiscal Year 2023 Financial ResultsMarch 22, 2024 | prnewswire.comMoleculin Reports Full Year 2023 Financial ResultsMarch 21, 2024 | investing.comMoleculin Biotech announces 1-for-15 reverse stock splitMarch 21, 2024 | benzinga.comA Preview Of Moleculin Biotech's EarningsMarch 20, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Announces Reverse Stock SplitMarch 20, 2024 | prnewswire.comMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and WebcastMarch 20, 2024 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.comMarch 19, 2024 | finance.yahoo.comMoleculin Announces Reverse Stock SplitMarch 12, 2024 | finance.yahoo.comMoleculin to Present at the 36th Annual ROTH ConferenceFebruary 6, 2024 | finance.yahoo.comHere's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn SituationJanuary 24, 2024 | finance.yahoo.comMoleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3December 21, 2023 | finance.yahoo.comMoleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-MarketDecember 15, 2023 | nasdaq.comHC Wainwright & Co. Initiates Coverage of Moleculin Biotech (MBRX) with Buy RecommendationSee More Headlines Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2023Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MBRX CUSIPN/A CIK1659617 Webwww.moleculin.com Phone(713) 300-5160FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$101.67 High Stock Price Target$240.00 Low Stock Price Target$20.00 Potential Upside/Downside+1,735.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($13.6432) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.91% Return on Assets-67.69% Debt Debt-to-Equity RatioN/A Current Ratio3.86 Quick Ratio7.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$27.33 per share Price / Book0.20Miscellaneous Outstanding Shares2,230,000Free Float2,078,000Market Cap$12.35 million OptionableNot Optionable Beta1.98 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Walter V. Klemp (Age 64)Founder, Chairman, President & CEO Comp: $894.54kMr. Jonathan P. Foster CPA (Age 60)Executive VP & CFO Comp: $611.17kDr. Donald H. Picker Ph.D. (Age 78)Chief Scientific Officer Comp: $486.44kDr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory BoardDr. Robert C. Shepard FACP (Age 72)M.D., Chief Medical Officer of Annamycin Dr. John Paul Waymack M.D. (Age 72)Sc.D., Senior Chief Medical Officer Dr. Sandra L. Silberman M.D. (Age 69)Ph.D., Chief Medical Officer of New Products Dr. Wolfram C. M. Dempke M.B.A.M.D., Ph.D., European Chief Medical OfficerMs. Jacqueline Northcut (Age 62)Consultant Comp: $51.11kMr. Louis Ploth Jr. (Age 70)Independent Advisor Comp: $118.49kMore ExecutivesKey CompetitorsPHAXIAM TherapeuticsNASDAQ:PHXMAlzamend NeuroNASDAQ:ALZNTharimmuneNASDAQ:THARNeurAxisNASDAQ:NRXSMinerva NeurosciencesNASDAQ:NERVView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCBought 64,652 shares on 2/15/2024Ownership: 0.194%Armistice Capital LLCBought 3,207,417 shares on 2/13/2024Ownership: 9.600%Atticus Wealth Management LLCBought 50,001 shares on 1/17/2024Ownership: 0.168%Walter V KlempBought 12,560 shares on 12/26/2023Total: $129,996.00 ($10.35/share)Jonathan P FosterBought 1,932 shares on 12/26/2023Total: $19,996.20 ($10.35/share)View All Insider TransactionsView All Institutional Transactions MBRX Stock Analysis - Frequently Asked Questions Should I buy or sell Moleculin Biotech stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBRX shares. View MBRX analyst ratings or view top-rated stocks. What is Moleculin Biotech's stock price target for 2024? 3 brokers have issued 12 month price objectives for Moleculin Biotech's stock. Their MBRX share price targets range from $20.00 to $240.00. On average, they anticipate the company's share price to reach $101.67 in the next twelve months. This suggests a possible upside of 1,555.8% from the stock's current price. View analysts price targets for MBRX or view top-rated stocks among Wall Street analysts. How have MBRX shares performed in 2024? Moleculin Biotech's stock was trading at $12.8760 at the beginning of the year. Since then, MBRX stock has decreased by 52.3% and is now trading at $6.14. View the best growth stocks for 2024 here. Are investors shorting Moleculin Biotech? Moleculin Biotech saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 2,100 shares, a drop of 98.4% from the February 29th total of 134,400 shares. Based on an average daily trading volume, of 28,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the shares of the stock are short sold. View Moleculin Biotech's Short Interest. When is Moleculin Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MBRX earnings forecast. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech, Inc. (NASDAQ:MBRX) issued its earnings results on Friday, August, 11th. The company reported ($3.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.20) by $1.20. During the same period in the prior year, the company earned ($3.60) earnings per share. When did Moleculin Biotech's stock split? Moleculin Biotech's stock reverse split before market open on Friday, March 22nd 2024. The 1-15 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL). Who are Moleculin Biotech's major shareholders? Moleculin Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.60%), Citadel Advisors LLC (0.19%) and Atticus Wealth Management LLC (0.17%). Insiders that own company stock include Jonathan P Foster, Robert E George and Walter V Klemp. View institutional ownership trends. How do I buy shares of Moleculin Biotech? Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MBRX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.